Sublicensing Fee Sample Clauses

Sublicensing Fee. Licensee shall pay MCGRI [*] of any fees or payments or remuneration paid to LICENSEE by a Sublicensee in relation to this License and for rights to all or part of the Licensed Patents (other than research funding, equity, loans or patent costs or fee

Sublicensing Fee. In addition to the amounts owed by NewLink to CIHS pursuant to Section 3.0, 3.1, 3.2, and 3.3 above, if NEWLINK grants a sublicense of its rights hereunder to a Third Party, NEWLINK agrees to pay to CIHS a sublicensing fee of [*] of any [*] and other consideration (other than [*] or [*] on [*], and [*] within [*] of [*]) (collectively, the “Sublicensing Fee”) received by NEWLINK from each Sublicensee in consideration for the grant of a sublicense of the Licensed Patents or development of a Licensed Product.

Sublicensing Fee. Licensee will pay Licensor [__]% of all sublicense fees received by Licensee from sublicenses that are not earned royalties.

Sublicensing Fee. In further partial consideration of the License, Avro shall pay to UHN [***] percent ([***]%) of all Sublicensing Revenue (the “Sublicensing Fee”). Any amounts paid to UHN further to Section 4.2 (License Maintenance/Upfront Fee) and Article 5 (Milestones) shall be creditable by Avro against amounts due to UHN further to this Section 4.6; however, the payments further to Section 4.2 and Article 5 shall not act as a cap on the payments owed further to this Section 4.6. To the extent that patent rights, other intellectual property rights or other rights or obligations other than Licensed Technology are licensed, sublicensed or granted by Avro in addition to the Licensed Technology for which the Sublicensing Revenue is attributable, that portion of the consideration received by Avro and subject to this Section 4.6 shall be equitably apportioned between the Licensed Technology and those other rights and obligations, and such apportionment shall be reasonable and in accordance with customary standards in the industry. Avro shall promptly deliver to UHN a written report setting forth such apportionment. In the event UHN disagrees with the determination made by Avro, UHN shall so notify Avro within [***] of receipt of Avro’s report and the Parties shall meet to discuss and resolve such disagreement in good faith. If the Parties are unable to agree in good faith as to such fair market values within [***] then (a) the matter shall be submitted in accordance with the dispute resolution process set forth in Article 14, and (b) UHN shall not be entitled to terminate this Agreement until a final determination has been made pursuant to Section 14.3.

Sublicensing Fee. POINT shall pay to the Licensor a [***] percent ([***]%) sublicensing fee (“Sublicensing Fee”) on all payments and revenues (in addition to [***]% of Net Sales) received by POINT in the nature of compensation for the sublicensing of the Product (and/or any associated Licensed Technology), provided that where POINT has made a Sublicensee responsible for all or part of a Milestone Payment, such Milestone Payment will not be considered to form part of POINT’s compensation as aforesaid except to the extent where milestone payments received by POINT from Sublicensee are in excess of the Milestone Payment owed to Licensor, wherein POINT shall pay to Licensor [***] percent ([***]%) of such excess plus such Milestone Payment. POINT shall however be liable for any failure of any of its Sublicensees to make all or part of a Milestone Payment. Notwithstanding the foregoing, this Section 9.5(a) and Sublicensing Fee shall not apply to POINT for sublicenses granted to any POINT Affiliate.

Sublicensing Fee. (a) Licensee shall not enter into negotiations with Sublicensees and shall not enter into any Sublicense Agreement without the written consent of an authorized officer of the Licensor and as otherwise provided in this Agreement. (b) All revenues generated by Licensee and/or Sublicensees (including First Sublicensee) shall be included in the Revenue calculation. Licensee is not allowed to enter into any side agreement, explicit or implicit, verbal or in writing, with Sublicensee, its affiliates or any third party with a view to circumvent Licensee’s contractual obligations towards Licensor, reduce the amount of Net Revenue or reduce the Earned Royalty (“Side Agreement”). Evidence of a Side Agreement shall be considered an Incurable Material Breach of this Agreement and shall promptly give Licensor the right to terminate this Agreement upon notice, collect any Earned Royalty that would have been due to Licensor but for the Side Agreement, and avail itself of any other remedies at law or equity.

Sublicensing Fee. Licensee will pay KSU [ __ ]% of all sublicense fees received by Licensee from sublicenses that are not earned royalties.

Sublicensing Fee. Licensee shall not enter into negotiations with Sublicensees and shall not enter into any Sublicense Agreement without the written consent of an authorized officer of the Licensor and as otherwise provided in this Agreement. A Sublicensing Fee may be agreed upon by the Parties at a later date.

Sublicensing Fee. For each third party that has entered into a Sublicense with Surrozen, Surrozen will pay [****] to Stanford (each, a PAGE 6 OF 26 S16-362:MW EXCLUSIVE LICENSE AGREEMENT 6/6/2018 “Sublicense Fee”). For avoidance of doubt, no such payment shall be made on the basis of Surrozen entering into an agreement with a third party performing activities on behalf Surrozen, such as a contract research organization, clinical trial site, or distributor.

Sublicensing Fee. In addition to the amounts owed by NewLink to CIHS pursuant to Section 3.0, 3.1, 3.2 and 3.3 above, if NEWLINK or an Affiliate of NEWLINK grants a sublicense of its rights hereunder to a Third Party, NEWLINK agrees to pay CIHS a sublicensing fee of [*] of any [*] and other consideration, and excluding: [*] or [*] payable to NEWLINK on [*] (collectively, the “Sublicensing Fee”) received by NEWLINK or an Affiliate of NEWLINK from each Sublicensee in consideration for the grant of a sublicense of the Licensed Patents or development of a Licensed Product.” 5. Newlink’s contact information in Section 9.0 is hereby replaced with: NEWLINK: NewLink Genetics Corporation 0000 X Xxxx Xxxxx Xxxx 0, Xxxxx 0000 Xxxx, XX 00000-0000